Programme
Programme roadmap
Communication and website milestones are listed separately from clinical development milestones for the planned Phase 2B CHR-P study with NWPT-SM32300. Status labels are qualitative only — completed, in progress, planned, or not confirmed publicly. We do not invent completion percentages or funds raised.
Last reviewed: 22 September 2026
Website milestones are not clinical progress. Publishing science pages or a synopsis does not mean ethics or regulatory approvals are granted, sites are activated, or recruitment has begun. Investigational programme — effectiveness in this population has not been established. This website is not a trial enrolment portal.
A. Communication / website milestones
-
Completed
Public science resources live
Publish informational science, evidence, glossary and related pages for patients, families, clinicians and researchers.
Evidence: Live pages on this site (Science, Evidence, Glossary and related)
-
Completed
Programme synopsis / Phase 2B overview published
Publish a public programme synopsis and Phase 2B overview describing the planned study at a high level.
Evidence: Public synopsis and Phase 2B overview pages on this site
-
Completed
Investigational formulation described
Describe NWPT-SM32300 publicly as the investigational oral CBD micellar softgel candidate for the CHR-P programme.
Evidence: Public product description on Science, Programme and public synopsis; investigational — effectiveness not established
B. Clinical development milestones (Phase 2B)
-
In progress
Study preparation
Finalise operational design for the proposed Phase 2B study (sites, synopsis lock, budget and operational package).
Evidence: Working public synopsis and planning materials; full operational finalisation ongoing
-
Not confirmed publicly
Applicable approvals
Obtain ethics, regulatory and other applicable approvals required before site activation.
Evidence: Not confirmed in public materials
-
Planned
Site activation
Contract and activate participating clinical sites under the approved protocol.
Evidence: Depends on approvals and operational readiness
-
Planned
Recruitment
Enrol eligible participants into the Phase 2B study.
Evidence: Follows site activation; this website is not an enrolment portal
-
Planned
Follow-up
Complete treatment and follow-up assessments per protocol (including week-16 follow-up in the working design).
Evidence: Follows recruitment
-
Planned
Analysis
Analyse primary and secondary outcomes and report findings according to the statistical analysis plan.
Evidence: Follows follow-up and database lock
Machine-readable copy: assets/roadmap.json. Money interfaces stay off on this public site. Public registration for updates is separate from any private diligence path.